|
Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers. Hence, anti-IL6 agents have been sought. The first approved medication in this class, tocilizumab (Actemra), is an antibody directed against the IL6-receptor. The second, siltuximab (Sylvant), is directed against IL-6 itself.〔〔http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf〕 Several agents are in clinical trials: sarilumab,〔http://www.clinicaltrials.gov/ct2/results?term=sarilumab〕 olokizumab (CDP6038)〔http://www.pharmatimes.com/article/12-09-28/UCB_s_RA_drug_does_not_overly_impress_in_Phase_II.aspx〕 elsilimomab, ALD518/BMS-945429, sirukumab (CNTO 136), and CPSI-2364 an apparent macrophage-specific inhibitor of the p38 mitogen-activated protein kinase pathway.〔PMID: 23598944〕 Agents in pre-clinical development include ARGX-109,〔http://www.prnewswire.com/news-releases/ruiyi-formerly-anaphore-and-argen-x-announce-exclusive-worldwide-license-agreement-for-argx-109-a-novel-anti-il-6-antibody-172634271.html〕 FE301,〔 FM101 ==Exercise induced IL-6 may be beneficial== New research has found IL-6 to be an anti-inflammatory cytokine with multiple beneficial effects when released by contracting muscle as a myokine. IL-6 had previously been classified as a proinflammatory cytokine. Therefore, it was first thought that the exercise-induced IL-6 response was related to muscle damage.〔Bruunsgaard H, Galbo H, Halkjaer-Kristensen J, Johansen TL, MacLean DA, Pedersen BK. Exercise-induced increase in interleukin-6 is related to muscle damage. J Physiol Lond 499: 833-841, 1997.〕 However, it has become evident that eccentric exercises are not associated with a larger increase in plasma IL-6 than exercise involving concentric “nondamaging” muscle contractions. This finding demonstrates that muscle damage is not required to provoke an increase in plasma IL-6 during exercise. In fact, eccentric exercise may result in a delayed peak and a much slower decrease of plasma IL-6 during recovery.〔Muscle as a secretory organ. Pedersen BK. American Physiological Society. Compr Physiol 3:1337-1362, 2013. http://www.inflammation-metabolism.dk/index.php?pageid=21&pmid=23897689〕 Anti-IL-6 therapies should therefore take into consideration the (beneficial) anti-inflammatory effects of myokines generally, including the now-established multiple benefits of muscle-derived Interleukin 6.〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Anti-IL-6」の詳細全文を読む スポンサード リンク
|